Warfarin Pharmacogenetics: Challenges and Opportunities for Clinical Translation by Nita A. Limdi
OpiniOn Article
published: 17 October 2012
doi: 10.3389/fphar.2012.00183
Warfarin pharmacogenetics: challenges and opportunities for 
clinical translation
Nita A. Limdi1,2*
1 Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA
2 Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA
*Correspondence: nlimdi@uab.edu
Edited by:
Andrea Gaedigk, The Children’s Mercy Hospital and Clinics, USA
Reviewed by:
Andrea Gaedigk, The Children’s Mercy Hospital and Clinics, USA
Stuart Scott, Mount Sinai School of Medicine, USA
interactions, these recommendations do 
not tailor dosing to individual patients 
(Ageno et al., 2012).
Candidate gene studies
The recognition of genetic regulation of 
warfarin response has stimulated efforts 
aimed at quantifying this influence. The bulk 
of the evidence supports the influence of 
single nucleotide polymorphisms (SNPS) in 
two genes; Cytochrome P450 2C9 (CYP2C9; 
codes for the main enzyme involved in war-
farin metabolism) and Vitamin K epoxide 
reductase complex1 (VKORC1; encodes the 
vitamin K–epoxide reductase protein, the 
target enzyme of warfarin). The influence 
of SNPs in CYP2C9 and VKORC1 on war-
farin dose has been extensively assessed and 
reviewed (Wadelius et al., 2007, 2009; Limdi 
and Veenstra, 2008; Cavallari and Limdi, 
2009; Klein et al., 2009). This evidence 
provided the basis for the recent warfarin 
package insert update by the United States 
Food and Drug Administration (FDA).
Moreover clinical algorithms that can 
enable dose prediction incorporating 
patient-specific genetic and clinical infor-
mation have been developed and are freely 
available. Gage et al. (2008) have developed 
a dosing algorithm based on clinical and 
demographic factors (body surface area, 
age, target INR, amiodarone use, smoker 
status, race, current thrombosis) along 
with CYP2C9 (*2, *3, *5, and *6), VKORC1 
(−1639/3673G>A), GGCX (rs11676382), 
and CYP4F2 (V433M) polymorphisms. 
The algorithm is freely available at www.
warfarindosing.org and allows calcula-
tion of warfarin dose based on clinical and 
demographic factors alone (if genotype is 
not available). Incorporation of novel and 
potentially important genetic variants (such 
Despite its wide use over six decades, war-
farin therapy remains challenging due its 
narrow therapeutic index. The multitude of 
factors interacting with warfarin makes it 
difficult to maintain anticoagulation within 
the target International Normalized Ratio 
(INR) range (Ageno et al., 2012). Even 
within this range the dose requirements 
vary as much as 20-fold between patients.
Deviations in INR control with frequent 
over and under-anticoagulation are com-
mon (Chiquette et al., 1998; Chamberlain 
et al., 2001; Ansell et al., 2007), are asso-
ciated with poor outcomes with under-
anticoagulation (increasing the risk of 
thrombosis) and over-anticoagulation 
(increasing the risk of serious or fatal 
hemorrhage), demanding that anticoagu-
lation control be tightly regulated (Hylek 
and Singer, 1994; Hylek et al., 1996, 2000; 
Hylek, 2003; Wittkowsky, 2004; Wittkowsky 
and Devine, 2004; Hylek and Rose, 2009). 
These adverse outcomes have relegated war-
farin to the “top 10 drugs” for adverse drug-
related hospitalizations in the US (Budnitz 
et al., 2007, 2011). Between 2007 and 2009 
warfarin accounted for 33% of drug-related 
hospitalizations for adverse events in the US 
(Budnitz et al., 2011). The risk for hemor-
rhage is particularly elevated when the INR 
exceeds four, as well as during the initial 
months of therapy. Therefore it is critical 
to achieve a safe and effective level of anti-
coagulation for patients starting warfarin.
Current guidelines for initiation of 
therapy provided by the American College 
of Chest Physicians (ACCP) allow flexibil-
ity in selecting a starting dose of warfarin, 
suggesting 5–10 mg. Although the ACCP 
guidelines recommend lower (2.5–5 mg) 
doses recognizing the influence of age, 
comorbidities, nutritional status, and drug 
as CYP2C9*8) can further improve dosing 
prediction in African American patients 
(Cavallari et al., 2010; Cavallari and Perera, 
2012).
As demonstrated by multiple studies, 
including the work of the International 
Warfarin pharmacogenetics Consortium 
(IWPC), dosing based on clinical/demo-
graphic factors alone improves predic-
tion of stable therapeutic dose of warfarin 
(compared to the one-size-fits-all 5 mg/
day dose), specifically in patients that need 
≥7 mg/day or ≤3 mg/day. Furthermore 
inclusion of CYP2C9 and VKORC1 provide 
a substantial gain in improvement of dose 
prediction in 46% of patients (Klein et al., 
2009). The www.warfarindosing.org also 
allows the user to compute the estimated 
dose requirements based on the IWPC 
algorithm.
Both pharmacogenetic algorithms 
(Gage et al., 2008; Klein et al., 2009) require 
detailed mathematical calculations to pre-
dict warfarin dose. A simpler alternative is 
to refer to the genotype-stratified warfarin 
dose table recently added to the warfarin 
label by the U.S. FDA. Although pharma-
cogenetic algorithms are most accurate, the 
genotype-stratified warfarin dose table pro-
vides a more accurate dose prediction than 
empiric dosing (Finkelman et al., 2011).
The Clinical Pharmacogenetics 
Implementation Consortium (CPIC) 
of the National Institutes of Health 
Pharmacogenomics Research Network has 
developed guidelines to assist clinicians 
in the interpretation and use of CYP2C9 
and VKORC1 genotype data for estimat-
ing therapeutic warfarin dose to achieve 
an INR of 2–3, should genotype results be 
available to the clinician. These guidelines 
are published (Johnson et al., 2011) and 
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Pressing Challenges
1. Will pharmacogenetic/genomic inter-
ventions have an impact on clinically 
meaningful outcomes?
Although extensive research efforts 
have identified several genetic markers 
strongly associated with outcomes of 
interest and hailed them as promising 
tools, these proclamations are based 
mainly on associations rather than their 
evaluation as predictors. Moreover such 
evaluations must be based on clinically 
relevant hard-endpoints such as anti-
coagulation control, hemorrhage and 
health-care utilization and costs (Limdi 
and Veenstra, 2010).
At the crux of this debate are three 
questions:
a) Can a genetic risk factor (genetic mar-
ker) associated with an adverse (or 
beneficial) outcome be a clinically use-
ful predictor of that outcome? (clinical 
validity)
•	 CYP2C9 and VKORC1 genotypes 
are clinically useful predictors 
of warfarin dose in clinical trials 
(Anderson et al., 2007, 2012).
b) Can incorporation of the genetic factor 
predict risk of the outcome more accu-
rately than existing clinical models? 
(Clinical utility)
•	 Incorporation	 of	 CYP2C9 and 
VKORC1 genotypes provided supe-
rior warfarin dose prediction compa-
red with the clinical algorithm (or the 
fixed 5-mg dose algorithm; Klein et 
al., 2009; Anderson et al., 2007, 2012).
•	 The	 updated	 FDA	 package	 insert	
provides easy to use genotype-stra-
tified warfarin dose table. Although 
pharmacogenetic algorithms are 
most accurate, the genotype-strati-
fied warfarin dose tables provide a 
more accurate dose prediction than 
empiric dosing (Finkelman et al., 
2011).
c) Will the outcome predicted for indivi-
duals be sufficiently different to war-
rant a change in treatment decisions? 
(degree of clinical utility)
1) Incorporation of CYP2C9 and 
VKORC1 genotypes improves	 pre-
diction	 of	 warfarin	 doses as confir-
med by randomized clinical trials 
proving excellent insight into the 
periodically updated based on new develop-
ments in the field (http://www.pharmgkb.
org/page/cpic).
genome-wide assoCiation studies
To identify other genes/SNPs that can 
explain variability in warfarin dose two 
genome-wide association studies (GWAS) 
have been conducted. Among patients of 
European descent these studies have con-
firmed the influence of VKORC1, CYP2C9, 
and identified CYP4F2	as the main genes 
associated with dose (Cooper et al., 2008; 
Takeuchi et al., 2009; Cha et al., 2010). 
The genome-wide significance of the lat-
ter association remains to be confirmed. 
These studies suggest that identification of 
common variants in other genes exhibiting 
influence of magnitude similar to that of 
CYP2C9 and VKORC1 is unlikely, at least 
in Whites.
As these known variants in candidate 
genes account for a smaller percent of the 
variability in warfarin dose among Blacks, 
the IWPC is leading a GWA analysis in 
Blacks. Preliminary results of the ongoing 
GWAs meta-analysis were presented at the 
2011 American Heart Association meet-
ing (Perera et al., 2011). A parallel effort is 
planned to conduct a GWAs meta-analysis 
for multiple population groups (Whites, 
Asians, African American, Japanese, and 
Middle-Eastern).
Despite these efforts a large portion 
(40% among White and 60% among Blacks) 
of the variability in warfarin dose remains 
unexplained. Perhaps emerging genotyp-
ing technologies such as exome sequenc-
ing or whole genome sequencing will reveal 
important clues that can explain the miss-
ing heritability. In addition to interrogating 
genetic variation ongoing and future studies 
must assess in detail environmental (diet, 
smoking alcohol, etc.) and lifestyle (com-
pliance, exercise, etc.) factors with similar 
rigor. It is very likely that this along with 
gene-environment interactions holds the 
key to explaining the majority of the vari-
ability in response.
One group that remains unrepresented 
is the Hispanic/Spanish population. This is 
of great importance in the US as people of 
Hispanic descent accounted for more than 
half the growth in the population between 
2000 and 2010 and account for 16.3% of 
the US population (surpassing Blacks who 
account for 12.3%; U.S.Census Bureau, 2010).
effectiveness of utilizing pharma-
cogenetics in a real-world setting 
(Anderson et al., 2012).
2) Whether the benefits of pharmaco-
genetic guidance of warfarin dosing 
would translate into improved	antico-
agulation	control is being evaluated.
•	 Anderson	 et	 al.	 showed	 that	
pharmacogenetic-dosing resul-
ted in a higher percent time in 
target range (PTTR; 69 and 71% 
at 1 and 3 months compared to 
the control group (58 and 59% 
at 1 and 3 months; Anderson 
et al., 2012).
•	 The	 improvement	 in	 PTTR	
achieved by pharmacogenetic-
dosing (vs. standard dosing) is 
greater than that achieved by 
specialty anticoagulation cli-
nics (vs. usual medical care). 
Importantly, these benefits in the 
pharmacogenetic cohort accrued 
in a setting where warfarin-trea-
ted patients were typically mana-
ged by standard protocol by an 
anticoagulation service/clinic.
3) Observational cohort studies have 
demonstrated that possession of 
CYP2C9 variant allele increases the 
risk of hemorrhage (Aithal et al., 
1999; Margaglione et al., 2000; 
Higashi et al., 2002; Limdi et al., 
2008). Whether the increased risk 
can be mitigated and whether the 
benefits of pharmacogenetic gui-
dance of warfarin dosing would 
translate into a decrease in risk 
of hemorrhage remains to be 
determined.
Not unlike randomized clinical trials con-
ducted to prove drug efficacy and attain 
FDA approval, pharmacogenetic tests/
interventions are being held to higher 
standards. To gain acceptance (in practice 
with reimbursement) the test/interven-
tion must demonstrate improvement in 
intermediate endpoints (e.g., PTTR for 
warfarin) and preferably hard-endpoints 
(e.g., hemorrhage risk reduction) in ran-
domized clinical trials.
2. When will this evidence be available? 
Are we there yet?
A number of clinical trials studies have 
assessed whether dose prediction and 
anticoagulation control are superior in 
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Johnson, 2012; Pradaxa, 2012), warfarin 
remains the most widely used oral anti-
coagulant (25 million users) (Schirmer 
et al., 2010; Altman and Vidal, 2011; 
Cabral et al., 2011; Wittkowsky, 2011; 
Tzeis and Andrikopoulos, 2012). The 
Practice INNovation And CLinical 
Excellence (PINNACLE) registry 
focusing on patients with atrial fibrilla-
tion (AF) reports among patients who 
received oral anticoagulation, 87.4% 
were treated with warfarin while just 
12.6% were prescribed one of the two 
new oral anticoagulants (Cardiology, 
2012).
The oral anticoagulant market is 
expected to exceed $ 9 billion by 2014 
(Melnikova, 2009), driven by demo-
graphics of the aging population and 
increased incidence of cardiovascu-
lar disease, and the uptake of newly 
approved agents. Although the market 
share of DBG (and the newer agents) 
is expected to increase, its uptake is 
hindered by lack of monitoring, revers-
ibility, and expense. Almost 2 years after 
approval of DBG, warfarin remains the 
most widely used oral anticoagulant.
Despite the approval of four CYP2C9/
VKORC1	rapid throughput genotyping plat-
forms by the U.S. FDA over the last decade 
clinical implementation of genotype-guided 
dosing is lagging. Although genotype-
guided therapy improves dose prediction is 
recognized, evidence that such an interven-
tion will improve anticoagulation control, 
reduce risk of adverse events and health-care 
costs is limited. Results of ongoing clinical 
trials are expected to address these issues and 
will perhaps provide the much needed impe-
tus to reevaluate reimbursement for genetic 
testing and for wider implementation.
The challenges unique to pharmacog-
enomic efforts have created an intangible 
benefit for science and humanity. Of note, 
most genetic/genomic investigations have 
identified genes with small effect sizes. To 
enable these discoveries investigators step-
ping outside the conventional paradigm of 
lab-based investigative efforts formed con-
sortia to build collaborations across labora-
tories, departments, institutions, countries, 
and continents. Investigators within these 
consortia sharing a common goal, pooled 
unpublished data, working with complete 
strangers, while maintaining enviable focus 
NCT01305148) is a randomized blin-
ded interventional trial where 4300 
patients (age > 65 years) are to be ran-
domized to warfarin dosing based on 
the GenoSTAT test plus clinical factors, 
or clinical factors alone, using the war-
farindosing.org website. The primary 
aim is to determine if genotype-guided 
therapy reduces the incidence of war-
farin-related clinical events, including 
major hemorrhage and thromboembo-
lic events at 30 days and in fewer hospi-
talizations and/or deaths compared 
to clinically guided therapy at 90 days 
compared to clinically guided therapy.
Additional information on the trials 
below and others can be found at www.
clinicaltrials.gov. These trials will pro-
vide a robust data for efficacy/effective-
ness and cost effectiveness analysis and 
will provide the foundation for policy 
development.
Although detractors claim pharmaco-
genetics/genomics in general has not 
yielded information to justify the invest-
ment of effort and funds, progress in the 
genomics/genetics arena has been main-
tained a rapid pace compared to other 
fields in medicine. For warfarin, the first 
report identifying the CYP2C9 *2 poly-
morphism was published in 1994. With 
the discovery of VKORC1 in 2004 the 
field burgeoned with investigations in 
multiple populations across the world 
documenting the effect of CYP2C9 and 
VKORC1 on warfarin dose, anticoagu-
lation control, and risk of hemorrhage.
Twenty years from the report identifying 
the CYP2C9 *2 (10 years following the 
identification of VKORC1), the results 
of the first double-blinded randomized 
clinical trial (COAG trial) testing gen-
otype-guided dosing intervention are 
expected to be available.
3. Although the uptake of newly avai-
lable oral anticoagulants is slow, a 
frequently raised question is “Will 
warfarin or warfarin pharmacogene-
tics matter in the coming years?”
The introduction of Dabigatran (DBG; 
October 2010), Rivaroxaban (2011), 
and Apixaban (awaiting approval) is 
changing the landscape of anticoagula-
tion therapy (Melnikova, 2009; Weitz 
et al., 2012). Although the use of DBG 
is increasing (0.6 million users in the US; 
patients receiving pharmacogenetically 
guided dosing vs. standard dosing or 
on clinical factors excluding genotype. 
However trials to date have been limited 
by study design issues (not blinded, use 
of historic control group) and limited 
sample size. Nonetheless these studies 
have provided valuable information on 
effect sizes and genotype-specific expec-
tations which was valuable in the design 
of large ongoing randomized trials.
1. The Clarification	 of	 Optimal	
Anticoagulation	 through	 Genetics 
(COAG; NCT00839657) trial is a mul-
ticenter double-blind, randomized trial 
aims to determine whether the use of 
genetic and clinical information for 
selecting the dose of warfarin	 in 1022 
patients during the initial dosing period 
will lead to improvement in stability of 
anticoagulation at 4 weeks relative to a 
strategy that incorporates only clinical 
information (without genetics).
2. The EUropean	 Pharmacogenetics	 of	
AntiCoagulant	 Therapy	 (EU-PACT; 
NCT01119300) trials are single-blinded 
randomized controlled trials aiming to 
assess the safety and clinical utility of 
genotype-guided dosing of the three main 
coumarins used in Europe: acenocouma-
rol, phenprocoumon, and warfarin. The 
warfarin arm will recruit 900 (UK and 
Sweden) warfarin patients to determine 
if genotype-guided dosing vs. standard 
dosing improves PTTR at 3 months.
3. The Genetic	 InFormatics	 Trial (GIFT; 
NCT01006733) of Prevent DVT is a 
randomized controlled trial aiming 
to determine the benefit of genotype-
guided dosing vs. clinically guided 
dosing among 1600 participants (age 
65 years or older) in reducing the com-
posite endpoint: non-fatal VTE, non-
fatal major hemorrhage, death, and an 
INR > 4.0 at 1 month.
4.	 Pharmacogenetic-dosing	 of	 warfarin:	 a	
controlled	randomized	trial is led by the 
Taiwan Warfarin Consortium which 
aims to determine whether genotype-
guided dosing can improve safety (as 
measured by time to target INR and 
PTTR) of warfarin treatment in 600 
participants compared to clinically gui-
ded dosing.
5. Warfarin	 Adverse	 Events	 Reduction	
for	 Adults	 Receiving	 Genetic	 Testing	
at	 Therapy	 Initiation (WARFARIN; 
Limdi Warfarin pharmacogenetics: challenges and opportunities
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and relentless effort to advance science. 
Among the consortia, the IWPC has suc-
cessfully brought together >100 investigators 
from >25 institutions across >10 countries 
providing valuable contributions (Klein 
et al., 2009; Limdi et al., 2010; Perera et al., 
2011) to the pharmacogenetic literature and 
much needed insight to inform the design 
of ongoing clinical trials in five short years.
One has to but conduct a PubMed search 
for GWAS for their favorite disease/pheno-
type and scroll through the authors and con-
tributors list to understand the magnitude 
of such efforts, the network of collabora-
tors created and progress made. These col-
laborations will continue (beyond the single 
publication) to advance science and enable 
discoveries beyond what can be gaged solely 
by investments; past, current, and future.
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